Market Overview

Barclays Increases Pfizer Price Target

Related PFE
Pfizer's Medivation Receives FDA Approval For Prostate Cancer Drug XTANDI
Johnson & Johnson's Robust Pipeline Supports Its Above-Average Valuation
Why You (And Another Company) Should Buy Gilead - Dividend Sensei (Seeking Alpha)

In a report released Wednesday, Barclays analyst Mark Purcell increases his price target for Pfizer (NYSE: PFE) from $32 to $34 per share, maintaining an Equal-Weight rating.

Analyst at Barclays are more bullish on the pharmaceutical sector, favoring Pfizer's potential for organic growth. Purcell mentions Pfizer's near-term potential depends on the company's ability to change its tax structure, increase transactions through core operations and increase its pipeline to full potential.

Shares of Pfizer are up about one percent.

Latest Ratings for PFE

Oct 2016JefferiesDowngradesBuyHold
Sep 2016JefferiesMaintainsBuy
Aug 2016JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Barclays Mark PurcellPrice Target Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!